Rami Skaliter
Directeur/Membre du Conseil chez TIKCRO TECHNOLOGIES LTD.
Profil
Rami Skaliter is currently the Chief Executive Officer at Cell Cure Neurosciences Ltd., an External Director at Tikcro Technologies Ltd., and was previously the Chief Operating Officer at Quark Pharmaceuticals, Inc. He received an undergraduate degree from Ben-Gurion University of the Negev and graduate and doctorate degrees from Weizmann Institute of Science.
Postes actifs de Rami Skaliter
Sociétés | Poste | Début |
---|---|---|
TIKCRO TECHNOLOGIES LTD. | Directeur/Membre du Conseil | 01/01/2016 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Directeur des opérations | 01/01/1995 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | Directeur Général | 01/06/2017 |
Formation de Rami Skaliter
Ben-Gurion University of the Negev | Undergraduate Degree |
Weizmann Institute of Science | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
Tikcro Technologies Ltd.
Tikcro Technologies Ltd. BiotechnologyHealth Technology Tikcro Technologies Ltd. operates as a biopharmaceutical company. It pursues an early stage biotechnology project generating new antibodies for cancer treatment addressing immune modulation. This project is based on technology from the Weizmann Institute of Science in Israel. It promotes a new approach for the generation of antibodies which are expected to have selectivity and blocking capabilities and, as a result, are expected to effectively modulate the immune system. Tikcro Technologies was founded on December 14, 1999 and is headquartered in Hadera, Israel. | Health Technology |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |